Merger and acquisition (M&A) transactions are complex, driven by tight timelines. Cross-functional matters, whether involving disentanglement (separations) or integration (acquisitions), require prompt resolution. In life sciences, the complexity of transactions is increased by the highly regulated nature of the industry, and one of the most complex issues is the transfer of product registrations for medicines and medical devices. Organisations are typically experienced with managing a product through its lifecycle, however transferring a large number of product registrations in the context of an M&A transaction is an area where organisations usually lack internal capability and capacity.
Product registrations, also known as marketing authorisations, are product- or product group-specific licences granted by local health authorities or notified bodies when a product meets all regulatory requirements and standards for safety, efficacy and quality within their jurisdiction and that allows a company to sell and distribute the product. In the context of M&A, the transfer of marketing authorisations is essential to allow the product assets to be transferred to the buyer while maintaining supply continuity and compliance with local regulations. Change of product ownership triggered by a transaction needs to be announced and processed by the local regulatory authority, and timelines and rules vary between countries, requiring careful planning and execution. Following the transfer of marketing authorisations, the purchasing company is required to update the packaging of the products within a certain ’grace period’ during which it is still allowed to import the products with old packaging. The duration of grace periods varies, depending on the company’s relationship with the regulatory authority, and some countries do not grant any grace periods.
Failure to update registrations and the packaging in a timely manner will mean that the company is not allowed to import and distribute products in the country affected, resulting in stock-outs that impact patients’ well-being and the company’s revenues.
With years of experience in multimarket product registration transfers, Deloitte understands the challenges that life science organisations face in M&A transactions. Our experts have helped companies navigate these challenges successfully, ensuring effective product registration transfer across multiple markets.
Deloitte specialises in leading complex M&A transactions for life science companies. Our team advises and supports the management of the multifaceted aspects of product registration transfers, including master planning, regulatory affairs, quality, supply chain, legal, trade compliance, and artwork & labelling. Our step-by-step approach and proven framework empower clients to develop a robust and effective transfer strategy, minimising supply continuity risks while enhancing efficiency throughout the process.